Method for treating gynecological diseases
AssigneePregLem SA
InventorsJean-Pierre Gotteland, Valérie Boujac, Ernest Loumaye
Life of this patent
Estimating the term…
Abstract
The present invention relates generally to a combination for use in the treatment of gynaecological diseases and associated disabling symptoms thereof, in a subject in need thereof, said pharmaceutical combination for use comprising co-administering a suitable pharmaceutical composition for oral administration comprising a first progesterone receptor modulator and a pharmaceutical composition suitable for vaginal and/or intrauterine administration comprising a second progesterone receptor modulator.
Claims20
A method for treating a gynaecological disease or an associated symptom thereof in subject in need thereof;
- comprising administering to the subject,
- i) an oral pharmaceutical composition comprising about 5 to 20 mg ulipristal, a pharmaceutically acceptable salt thereof, or an active metabolite thereof, daily from about 1 week to 3 months, followed by
- ii) a vaginal ring that releases about 0.1 to 20 mg ulipristal, a pharmaceutical acceptable salt thereof, or an active metabolite thereof, daily from about 1 week to 1 year,
- wherein the gynaecological disease or associated symptom thereof is adenomyosis,
- wherein the method treats the gynaecological disease or associated symptom thereof, and
- wherein the active metabolite thereof is CDB-3877, CDB-3963, CDB-3236, CDB-4183, or a combination thereof.
A method for treating adenomyosis in a premenopausal woman in need thereof, comprising administering to the woman,
- i) an oral pharmaceutical composition comprising about 5 mg ulipristal acetate or an active metabolite thereof, daily from about 1 week to 3 months, followed by
- i) a vaginal pharmaceutical composition that releases about 1 mg ulipristal acetate daily, from about 1 week to 1 year,
- wherein the method treats adenomyosis, and
- wherein the active metabolite thereof is CDB-3877, CDB-3963, CDB-3236, CDB-4183, or a combination thereof.
A method for treating adenomyosis in a subject in need thereof, comprising administering to the subject,
- i) an oral pharmaceutical composition comprising about 5 to 20 mg ulipristal acetate daily from about 1 week to 1 month, followed by
- ii) a vaginal ring that releases about 0.25 to 5 mg ulipristal acetate daily from about 1 week to 3 months,
- wherein the method treats adenomyosis.
Dependencies are inferred from the claim text.